Literature DB >> 28594453

Risk Factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India.

S Kansal1, J Chakravarty1, A Kumar1, P Malaviya1, M Boelaert2, E Hasker2, B Ostyn2, S Sundar1.   

Abstract

OBJECTIVE: To assess the rate of default from treatment in the visceral leishmaniasis (VL) elimination programme and to identify risk factors and its underlying causes.
METHODS: Case-control study conducted between December 2009 and June 2012 in three primary health centres (PHCs) of Muzaffarpur district, India. Patients who defaulted from treatment from the PHCs were considered as 'cases' and those who completed their treatment as 'controls'. Two controls were included in the study for each case. Respondents' opinion and satisfaction with the services provided at the PHCs were also elicited. Logistic regression was performed to assess the contribution of sociodemographic variables on patient status, and a discriminant analysis was used (after decomposing the original data) to identify factors that can predict the patient status as defaulter or not, based on factor scores of the components as predictor variables.
RESULTS: During the study period, 16.3% (89/544) of patients defaulted; 87 cases and 188 controls were interviewed through a semistructured questionnaire. Women tended to be more at risk for default (OR, 1.6, 95% CI (0.9 -2.9). Treatment received was miltefosine in 55.6% and sodium stibogluconate (SSG) in 44.4%. Most (86%) defaulters completed their treatment at other healthcare facilities; 70% of them preferred non-governmental institutions. Most cited reasons for default were seeking a second opinion for VL treatment and preferring to be treated in specialised VL centres. Discriminant analysis showed only one significant predictor: dissatisfaction with the medical care received in PHCs.
CONCLUSION: Efforts are needed to enhance the quality of VL care at PHC level, which will be beneficial in increasing treatment completion rates.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990CAPzzm321990; zzm321990PHCzzm321990; Inde; India; Leishmaniose viscérale; Leishmaniosis Visceral; defaulter; désistement; incumplimiento; primary health centre; visceral leishmaniasis

Mesh:

Substances:

Year:  2017        PMID: 28594453      PMCID: PMC6345645          DOI: 10.1111/tmi.12906

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  11 in total

1.  World Bank funds private hospital in India.

Authors:  G Yamey
Journal:  BMJ       Date:  2001-02-03

2.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

Authors:  S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

3.  Drug resistance in Indian visceral leishmaniasis.

Authors:  S Sundar
Journal:  Trop Med Int Health       Date:  2001-11       Impact factor: 2.622

4.  A Study Of A Measure Of Sampling Adequacy For Factor-Analytic Correlation Matrices.

Authors:  B A Cerny; H F Kaiser
Journal:  Multivariate Behav Res       Date:  1977-01-01       Impact factor: 5.923

5.  Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India.

Authors:  Shri P Singh; Dandu C S Reddy; Rabindra N Mishra; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2006-09       Impact factor: 2.345

6.  Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.

Authors:  Shyam Sundar; Dinesh Mondal; Suman Rijal; Sujit Bhattacharya; Hashim Ghalib; Axel Kroeger; Marleen Boelaert; Philippe Desjeux; Heide Richter-Airijoki; Gundel Harms
Journal:  Trop Med Int Health       Date:  2008-01       Impact factor: 2.622

7.  Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project.

Authors:  Bart Ostyn; Paritosh Malaviya; Epco Hasker; Surendra Uranw; Rudra P Singh; Suman Rijal; Shyam Sundar; Jean-Claude Dujardin; Marleen Boelaert
Journal:  Trop Med Int Health       Date:  2013-03-07       Impact factor: 2.622

8.  Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa.

Authors:  Candace M Miller; Mpefe Ketlhapile; Heather Rybasack-Smith; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2010-06       Impact factor: 2.622

9.  Incidence, time and determinants of tuberculosis treatment default in Yaounde, Cameroon: a retrospective hospital register-based cohort study.

Authors:  Eric Walter Pefura Yone; André Pascal Kengne; Christopher Kuaban
Journal:  BMJ Open       Date:  2011-11-24       Impact factor: 2.692

10.  Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and bangladesh.

Authors:  Megha Raj Banjara; Siddhivinayak Hirve; Niyamat Ali Siddiqui; Narendra Kumar; Sangeeta Kansal; M Mamun Huda; Pradeep Das; Suman Rijal; Chitra Kumar Gurung; Paritosh Malaviya; Byron Arana; Axel Kroeger; Dinesh Mondal
Journal:  J Trop Med       Date:  2012-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.